Payment overview · 2025
General Payments
$49,881.83
122 reported records · 21 companies
Healthcare provider profile · identity verified
David Stewart, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · CHICAGO, IL · NPI 1700042389
Verified facts
What the public records show
CMS Open Payments records show David Stewart, M.D. received $49,881.83 in general payments during 2025 across 122 reported records.
Medtronic, Inc. accounted for 92.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 603 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 603 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$46,158.26 | 92.5% | 68 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $943.91 | 1.9% | 3 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $823.99 | 1.6% | 6 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $299.82 | 0.6% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $258.66 | 0.5% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $207.64 | 0.4% | 14 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $151.32 | 0.3% | 1 | 2025 |
| ENDOTRONIX, INC. | Unresolved — no canonical attribution shown | $146.96 | 0.3% | 1 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $142.48 | 0.3% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $142.39 | 0.3% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $127.34 | 0.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $125.50 | 0.2% | 5 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $118.98 | 0.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $73.64 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.43 | 0.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $28.00 | 0.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.60 | 0.0% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $19.23 | 0.0% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $18.84 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.41 | 0.0% | 1 | 2025 |
| Thrombolex, Inc. | Unresolved — no canonical attribution shown | $12.43 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,780.00 | 9 |
| Travel and Lodging | $5,830.22 | 26 |
| Food and Beverage | $5,271.61 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $17,540.34 | 19 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $12,800.61 | 6 | 2025 |
Source payment records
|
|||||
| MO.MA ULTRA Normalized: mo ma ultra |
Device | Medtronic, Inc. | $2,896.58 | 18 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $943.91 | 3 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $823.99 | 6 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $348.65 | 4 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $299.82 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $258.66 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $207.64 | 14 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $199.81 | 2 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $151.32 | 1 | 2025 |
Source payment records
|
|||||
| CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Normalized: cordella pulomonary artery pressure sensor |
Device | ENDOTRONIX, INC. | $146.96 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $142.48 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $127.34 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $125.50 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.43 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $28.00 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| SAVVYWIRE Normalized: savvywire |
Device | CARDIVA MEDICAL, INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| Bashir Endovascular Catheter Normalized: bashir endovascular catheter |
Device | Thrombolex, Inc. | $12.43 | 1 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $1.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
603 | 168 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
206 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
603 | 168 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1215 | 390 |
| Metoprolol Succinate | Metoprolol Succinate | 1191 | 377 |
| Clopidogrel | Clopidogrel Bisulfate | 1094 | 380 |
| Furosemide | Furosemide | 773 | 280 |
| Amlodipine Besylate | Amlodipine Besylate | 695 | 228 |
| Eliquis | Apixaban | 603 | 168 |
| Hydrochlorothiazide | Hydrochlorothiazide | 500 | 171 |
| Carvedilol | Carvedilol | 471 | 150 |
| Lisinopril | Lisinopril | 434 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 338 | 128 |
| Losartan Potassium | Losartan Potassium | 337 | 119 |
| Metoprolol Tartrate | Metoprolol Tartrate | 312 | 98 |
| Irbesartan | Irbesartan | 294 | 98 |
| Xarelto | Rivaroxaban | 267 | 77 |
| Entresto | Sacubitril/Valsartan | 206 | 64 |
| Bumetanide | Bumetanide | 200 | 84 |
| Spironolactone | Spironolactone | 191 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 75 |
| Warfarin Sodium | Warfarin Sodium | 163 | 56 |
| Repatha Sureclick | Evolocumab | 159 | 35 |
| Simvastatin | Simvastatin | 149 | 50 |
| Potassium Chloride | Potassium Chloride | 145 | 57 |
| Ezetimibe | Ezetimibe | 138 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 120 | 41 |
| Brilinta | Ticagrelor | 119 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 42 |
| Nifedipine Er | Nifedipine | 91 | 36 |
| Clonidine | Clonidine | 72 | 14 |
| Clonidine Hcl | Clonidine Hcl | 70 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | 17 |
| Midodrine Hcl | Midodrine Hcl | 54 | 25 |
| Praluent Pen | Alirocumab | 54 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 21 |
| Farxiga | Dapagliflozin Propanediol | 50 | 17 |
| Flecainide Acetate | Flecainide Acetate | 46 | 16 |
| Atenolol | Atenolol | 45 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 15 |
| Nitroglycerin | Nitroglycerin | 43 | 17 |
| Sotalol | Sotalol Hcl | 39 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 13 |
| Valsartan | Valsartan | 35 | 13 |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 31 | 11 |
| Klor-Con M20 | Potassium Chloride | 30 | 11 |
| Digoxin | Digoxin | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | 22 |
| Ramipril | Ramipril | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 21 |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Torsemide | Torsemide | 18 | 11 |
| Dofetilide | Dofetilide | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | 11 |
| Captopril | Captopril | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49,881.83 · 122 records | Medtronic, Inc. | ABRE, Alto Abdominal Stent Graft System, Asahi Coronary Wires, Bashir Endovascular Catheter, CAMZYOS, CARDIOMEMS, CHOCOLATE PTA BALLOON CATHETER, CORDELLA PULOMONARY ARTERY PRESSURE SENSOR, COREVALVE EVOLUT R, Coronary Other, Da Vinci Surgical System, FFRct, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, HAWKONE, LEQVIO, MO.MA ULTRA, REPATHA, SAVVYWIRE, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TURBOHAWK, VENASEAL, VERQUVO, VYNDAQEL, Venovo | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error